MX2021009702A - Metodos para tratar el dolor de la superficie ocular. - Google Patents

Metodos para tratar el dolor de la superficie ocular.

Info

Publication number
MX2021009702A
MX2021009702A MX2021009702A MX2021009702A MX2021009702A MX 2021009702 A MX2021009702 A MX 2021009702A MX 2021009702 A MX2021009702 A MX 2021009702A MX 2021009702 A MX2021009702 A MX 2021009702A MX 2021009702 A MX2021009702 A MX 2021009702A
Authority
MX
Mexico
Prior art keywords
ocular surface
methods
treating ocular
surface pain
treating
Prior art date
Application number
MX2021009702A
Other languages
English (en)
Spanish (es)
Inventor
Muneto Mogi
Quintus Medley
Michela Montecchi-Palmer
Kalliopi Stasi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021009702A publication Critical patent/MX2021009702A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021009702A 2019-02-15 2020-02-13 Metodos para tratar el dolor de la superficie ocular. MX2021009702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806682P 2019-02-15 2019-02-15
PCT/IB2020/051210 WO2020165838A1 (en) 2019-02-15 2020-02-13 Methods for treating ocular surface pain

Publications (1)

Publication Number Publication Date
MX2021009702A true MX2021009702A (es) 2021-09-14

Family

ID=69740423

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009702A MX2021009702A (es) 2019-02-15 2020-02-13 Metodos para tratar el dolor de la superficie ocular.
MX2025000353A MX2025000353A (es) 2019-02-15 2021-08-12 Metodos para tratar el dolor de la superficie ocular

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025000353A MX2025000353A (es) 2019-02-15 2021-08-12 Metodos para tratar el dolor de la superficie ocular

Country Status (17)

Country Link
US (4) US20200261456A1 (cg-RX-API-DMAC7.html)
EP (1) EP3923909A1 (cg-RX-API-DMAC7.html)
JP (3) JP7571037B2 (cg-RX-API-DMAC7.html)
KR (1) KR102977683B1 (cg-RX-API-DMAC7.html)
CN (1) CN113453686B (cg-RX-API-DMAC7.html)
AU (2) AU2020222348B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015998A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130038A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002152A1 (cg-RX-API-DMAC7.html)
IL (1) IL284629A (cg-RX-API-DMAC7.html)
JO (1) JOP20210217A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021009702A (cg-RX-API-DMAC7.html)
PH (1) PH12021551968A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202107260VA (cg-RX-API-DMAC7.html)
TW (2) TW202515576A (cg-RX-API-DMAC7.html)
WO (1) WO2020165838A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104593B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
US12459902B2 (en) * 2020-08-06 2025-11-04 Bausch + Lomb Ireland Limited Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof
CN119184616A (zh) * 2024-09-03 2024-12-27 中山大学附属第三医院粤东医院(梅州市梅县区人民医院) 一种疼痛等级的测评方法及其评估系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US20100152209A1 (en) 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP2009521484A (ja) 2005-12-22 2009-06-04 プロレキシーズ ファーマシューティカルズ インコーポレイテッド 3−アリール置換キナゾロンおよびその使用
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
ES2648225T3 (es) 2007-07-18 2017-12-29 Novartis Ag Combinaciones sinérgicas de antagonistas de VR-1 e inhibidores de COX-2
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
WO2009089057A1 (en) 2008-01-09 2009-07-16 Renovis, Ins. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009149239A1 (en) 2008-06-04 2009-12-10 Children's Medical Center Corporation Methods of modulating angiogenesis via trpv4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2390327A1 (en) 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
AU2017330620A1 (en) 2016-09-20 2019-03-28 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產(第二)有限公司 Trpv4拮抗劑
JP2019532054A (ja) 2016-09-20 2019-11-07 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Trpv4拮抗薬
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
JP2022520410A (ja) 2019-02-15 2022-03-30 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの結晶形態及びその製剤

Also Published As

Publication number Publication date
AU2023203716B2 (en) 2025-03-20
MX2025000353A (es) 2025-02-10
US20220193078A1 (en) 2022-06-23
BR112021015998A2 (pt) 2021-10-05
KR20210129677A (ko) 2021-10-28
JP7571037B2 (ja) 2024-10-22
ZA202104593B (en) 2025-03-26
KR102977683B1 (ko) 2026-06-16
TWI878266B (zh) 2025-04-01
CN113453686B (zh) 2025-04-15
AU2020222348A1 (en) 2021-08-05
US20210275529A1 (en) 2021-09-09
WO2020165838A9 (en) 2021-03-18
JOP20210217A1 (ar) 2023-01-30
US11234982B2 (en) 2022-02-01
JP2022520832A (ja) 2022-04-01
AU2020222348B2 (en) 2023-03-16
TW202515576A (zh) 2025-04-16
CL2021002152A1 (es) 2022-04-18
TW202045179A (zh) 2020-12-16
US20200261456A1 (en) 2020-08-20
IL284629A (en) 2021-08-31
JP2025004186A (ja) 2025-01-14
PH12021551968A1 (en) 2022-05-23
US20240342174A1 (en) 2024-10-17
EP3923909A1 (en) 2021-12-22
WO2020165838A1 (en) 2020-08-20
AU2023203716A1 (en) 2023-07-06
SG11202107260VA (en) 2021-08-30
JP2026097970A (ja) 2026-06-16
CN113453686A (zh) 2021-09-28
CA3130038A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
JOP20210224A1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل)- بنزونيتريل
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
EP4338804A3 (en) Epinephrine spray formulations
MX2025000353A (es) Metodos para tratar el dolor de la superficie ocular
JOP20210050A1 (ar) معدلات تعبير pnpla3
EA202092748A1 (ru) Модуляторы экспрессии apol1
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
EA201990400A1 (ru) Соединения и композиции и их применение
EA202191519A1 (ru) Модуляторы trex1
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
SG11202011010YA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
EA202090180A1 (ru) Композиции nk1-антагониста и способы лечения депрессии
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2023002851A (es) Tratamiento de la enfermedad de parkinson.
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
SA522431572B1 (ar) مركب بيريميدين-5-كربوكساميد
JOP20210009A1 (ar) طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
MX2021010603A (es) Inhibidores de caspasa y metodos de uso de los mismos.
MX2019002629A (es) Formas cristalinas de compuestos terapéuticos y usos de los mismos.
EA202191657A1 (ru) Модуляторы экспрессии hsd17b13